EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

UBE 2 C ‐Mediated CD 147‐ CTLA ‐4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer

Xuwei Hong, Ting Hong, Xinyu Liu, Peixiu Yao, Weiqiang Lin, Guoyuan Liu, Huihong Guan, Yonghai Zhang iD

Cancer Science · 2026-09 · 117 (9) · 2366-2378

DOI: 10.1111/cas.70430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 27.05.2026. Verfasst von Xuwei Hong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Shantou Central Hospital, Shantou, China. Hauptthemen laut MEDLINE: CTLA-4 Antigen, Basigin, Ubiquitin-Conjugating Enzymes, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Science and Technology Planning Projects of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite immune checkpoint inhibitors (ICIs) having benefited bladder cancer (BCa) patients, their limited response rates urge elucidation of intrinsic resistance mechanisms. In this study, we demonstrated that ubiquitin conjugating enzyme E2C (UBE2C) promotes the proliferation, invasion, and migration of BCa and inhibits DNA damage, accompanied by a decrease in T cell abundance. In syngeneic C57BL/6 BCa models and BCa–CD8 + T‐cell cocultures, UBE2C silencing reduced CD147 and CTLA‐4 abundance, restored IFN‐γ, TNF‐α, and TGF‐β secretion, expanded CD3 + CD8 + subsets, and attenuated tumor growth, invasion, and migration. Conversely, UBE2C or CD147/CTLA‐4 overexpression reinstated T‐cell exhaustion and malignant progression. Targeting the UBE2C–CD147–CTLA‐4 axis resensitizes BCa to immune attack, offering a rational strategy to extend the efficacy of current immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CTLA-4 AntigenBasiginUbiquitin-Conjugating EnzymesUrinary Bladder NeoplasmsTumor MicroenvironmentAnimalsHumansT-Cell ExhaustionMiceMice, Inbred C57BLCell Line, TumorCD8-Positive T-LymphocytesCell ProliferationCell MovementFemale

Stichwörter der Autor:innen

CD147CTLA‐4T cell exhaustionUBE2Cbladder cancer

Substanzen

CTLA-4 AntigenBasiginUbiquitin-Conjugating EnzymesCTLA4 protein, humanBSG protein, human

Autor:innen und Institutionen

  • Department of Urology, Shantou Central Hospital, Shantou, China.
  • Shantou Key Laboratory of Basic and Translational Research of Malignant Tumors, Shantou, China.
  • Clinical Medical Research Center, Shantou Central Hospital, Shantou, China.
  • Department of Biobank, Shantou Central Hospital, Shantou, China.
  • Department of Oncology, Shantou Central Hospital, Shantou, China.

ORCID-Profile: Yonghai Zhang

Förderung

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Science and Technology Planning Projects of Guangdong Province
  • Science and Technology Program of Shantou City
  • Shantou Medical Health Science and Technology Project

Zitieren

APA

Hong, X., Hong, T., Liu, X., Yao, P., Lin, W., Liu, G., Guan, H., & Zhang, Y. (2026). UBE 2 C ‐Mediated CD 147‐ CTLA ‐4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer. Cancer Science, 117(9), 2366-2378. https://doi.org/10.1111/cas.70430

Vancouver

Hong X, Hong T, Liu X, Yao P, Lin W, Liu G, et al. UBE 2 C ‐Mediated CD 147‐ CTLA ‐4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer. Cancer Science. 2026;117(9):2366-2378. doi:10.1111/cas.70430

BibTeX
@article{Hong2026,
  author = {Hong, Xuwei and Hong, Ting and Liu, Xinyu and Yao, Peixiu and Lin, Weiqiang and Liu, Guoyuan and Guan, Huihong and Zhang, Yonghai},
  title = {UBE 2 C ‐Mediated CD 147‐ CTLA ‐4 Axis Promotes T Cell Exhaustion and Immunosuppressive Microenvironment in Bladder Cancer},
  journal = {Cancer Science},
  year = {2026},
  volume = {117},
  number = {9},
  pages = {2366--2378},
  doi = {10.1111/cas.70430}
}
Kostenlos starten →